HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Targeted therapies may be ‘game changer’ for CLL treatment
-
- Drug costs must be balanced with efficacy, side effects Timothy Graubert, MD
- Thrombosis and anticoagulation: Highlights from the ASH Annual Meeting Stephan Moll, MD
- Victory in cancer cure is not always as sweet as publicized Max J. Coppes, MD, PhD, MBA
- 2014: A big year for new oral anticoagulants Stephan Moll, MD
- Bleeding risk increased in patients with cancer-associated VTE, chronic kidney disease
- D-dimer thresholds reduced need for CT pulmonary angiography
- Stereotactic radiotherapy extended OS in oligometastatic cancer
- Age determined rate, clinical relevance of lapatinib-associated rash
-
- Axitinib yielded poor results in adrenocortical carcinoma
- BAP1 protein expression independent biomarker in low-risk clear-cell RCC
- Clinicians perceive poorer quality of life in patients with lung cancer
- Combination of chemotherapy, targeted drugs appears effective in advanced NSCLC
- Daily prenatal iron use increased birth weight
- High copayment linked to TKI nonadherence, discontinuation in CML
- High-dose fulvestrant reduced risk for death in ER-positive breast cancer
- Metastatic prostate cancer survival has not improved over time
-
- Metformin improved survival in patients with cancer, diabetes
- Pigmentation beyond scar’s edge strongly indicated recurrent melanoma
- Stage III, IV melanoma increased risk for new primary melanomas
- Stereotactic radiosurgery conferred long-term benefits in certain hemangioblastomas
- Suicide risk greater among adolescents, young adults with cancer
- Sunitinib effective in advanced sarcomatoid RCC
- Survivors of childhood ALL need continued support for neurocognitive impairments
- Hepcidin expression decreased by recombinant erythroferrone
-
- RAS status determined panitumumab benefit in colorectal cancer
- Ramucirumab plus paclitaxel improved OS, PFS in advanced gastric cancer
- Oral capecitabine may be new standard of care in rectal cancer
- EZH2, BCL6 together induce germinal center-derived lymphomas
- Potential mechanism found for high TP53 mutation incidence in therapy-related AML, myelodysplastic disorder
- Novel biomarker identified in myeloproliferative neoplasms
- Donor-derived allogeneic T cells may cause regression of B-cell malignancies
- Boxed warning draws attention to HBV reactivation Debbie Blamble, PharmD, BCOP
-